
浏览全部资源
扫码关注微信
纸质出版日期:2017
移动端阅览
玄瑛美, 张广平, 马丽娜, 等. 双黄调脂方及其有效成分发挥降脂作用的探讨[J]. 中国实验方剂学杂志, 2017,23(10):79-84.
XUAN Ying-mei, ZHANG Guang-ping, MA Li-na, et al. Anti-hyperlipidemia Effect of Shuanghuang Tiaozhi Prescription by Regulating CHO and TG Metabolism[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(10): 79-84.
玄瑛美, 张广平, 马丽娜, 等. 双黄调脂方及其有效成分发挥降脂作用的探讨[J]. 中国实验方剂学杂志, 2017,23(10):79-84. DOI: 10.13422/j.cnki.syfjx.2017100079.
XUAN Ying-mei, ZHANG Guang-ping, MA Li-na, et al. Anti-hyperlipidemia Effect of Shuanghuang Tiaozhi Prescription by Regulating CHO and TG Metabolism[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(10): 79-84. DOI: 10.13422/j.cnki.syfjx.2017100079.
目的:通过体内外实验研究双黄调脂方的降脂作用,探讨其降脂机制。方法:昆明种小鼠随机分为正常组、模型组、阳性药组(血脂康,0.6 g·kg-1)和双黄调脂高、低剂量组(22.5,7.5 g·kg-1),观察双黄调脂方对Trtion-WR1339诱导的高血脂模型的影响。基于整体实验,体外实验观察了双黄调脂主要有效成分姜黄素、黄连素、葛根素对油酸(oleic acid,OA)诱导的HepG2细胞模型胆固醇(CHO),甘油三酯(TG),3-羟基-3-甲基戊二酰CoA(HMG-CoA)还原酶,高密度脂蛋白胆固醇(HDL-C),低密度脂蛋白受体(LDL-R),胆固醇7α-羟化酶(CYP7A1)和脂蛋白脂酶(LPL)含量的影响,探讨其可能降脂途径。结果:与正常组比较,模型组小鼠血清CHO和TG含量显著升高(P<0.01);与模型组比较,双黄调脂方高剂量组能显著降低模型小鼠血清的CHO,TG水平(P<0.05,P<0.01)。体外实验中,与空白组比较,模型组细胞CHO,TG和HMG-CoA还原酶含量显著升高(P<0.05,P<0.01),HDL-C,LDL-R,CYP7A1和LPL含量显著降低(P<0.05);与模型组比较,姜黄素高剂量组(10 mg·L-1)能显著升高模型细胞HDL-C,LDL-R和LPL含量(P<0.05,P<0.01),降低TG和HMG-CoA含量(P<0.05,P<0.01);黄连素高剂量组(40 mg·L-1)能显著升高模型细胞CHO,HDL-C,LDL-R和CYP7A1含量(P<0.05,P<0.01);葛根素高剂量组(300 mg·L-1)能显著升高模型细胞HDL-C,LDL-R,CYP7A1和LPL含量(P<0.05,P<0.01),降低CHO,TG和HMG-CoA含量(P<0.05,P<0.01)。结论:双黄调脂方可通过抑制内源性胆固醇合成、促进胆固醇逆转运(RCT)途径和低密度脂蛋白(LDL)受体途径、促进胆固醇转化以及促进甘油三酯降解等多个途径来发挥降脂作用。
Objective: To study the effect of Shuanghuang Tiaozhi prescription in vivo and in vitro
in order to explore its lipid-lowering mechanism. Method: KM mice were randomly divided into normal control group
model group
positive drug group (Xuezhikang
0.6 g·kg-1)
high and low-dose Shuanghuang Tiaozhi prescription groups (22.5
7.5 g·kg-1). The effects of Shuanghuang Tiaozhi prescription on hyperlipidemic rat models induced by Triton-WR 1339 were studied. Based on the experiment in vivo
the effects of curcumin
berberine and puerarincan on the contents of cholesterol (CHO)
triglyceride (TG)
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase
high density lipoprotein cholesterol (HDL-C)
low-density lipoprotein receptor (LDL-R)
cholesterol 7a-hydroxylase (CYP7A1) and lipoprotein lipase (LPL) in HepG2 cells induced by oleic acid (OA) were studied to explore the ways of reducing blood lipid. Result: Compared with normal control group
serum CHO and TG content of model mice were significantly increased (P<0.01). Compared with model group
high-dose Shuanghuang Tiaozhi prescription (22.5 g·kg-1) can significantly decrease serum CHO and TG content of model mice (P<0.05
P<0.01). In vitro
compared with normal control group
CHO
TG and HMG-CoA reductase content of model cells significantly increased (P<0.05
P<0.01)
HDL-C
LDL-R
CYP7A and LPL content of model cells were significantly decreased (P<0.05). Compared with model group
high-dose curcumin (10 mg·L-1) can significantly increase HDL-C
LDL-R
LPL content and decrease TG
HMG-CoA content in model cells (P<0.05
P<0.01); high-dose berberine (40 g·L-1) can significantly increase CHO
HDL-C
LDL-R
CYP7A1 content in model cells (P<0.05
P<0.01); high-dose puerarincan (300 mg·L-1) can significantly increase HDL-C
LDL-R
CYP7A1
LPL content and decrease CHO
TG
HMG-CoA content in model cells (P<0.05
P<0.01). Conclusion: Shuanghuang Tiaozhi prescription can reduce blood lipid by inhibiting endogenous cholesterol synthesis
promoting RCT and LDL receptor pathway
cholesterol transformation and degradation of triglyceride.
0
浏览量
6
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621